

Benjamin Young

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11099030/publications.pdf>

Version: 2024-02-01

49
papers

2,810
citations

218677

26
h-index

233421

45
g-index

51
all docs

51
docs citations

51
times ranked

3264
citing authors

#	ARTICLE	IF	CITATIONS
1	The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. <i>Lancet, The</i> , 2006, 368, 476-482.	13.7	345
2	Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. <i>Lancet, The</i> , 2010, 375, 396-407.	13.7	276
3	Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study. <i>Journal of Infectious Diseases</i> , 2013, 207, 740-748.	4.0	271
4	Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naïve adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. <i>Lancet Infectious Diseases, The</i> , 2012, 12, 111-118.	9.1	260
5	Increased Rates of Bone Fracture Among HIV-Infected Persons in the HIV Outpatient Study (HOPS) Compared With the US General Population, 2000-2006. <i>Clinical Infectious Diseases</i> , 2011, 52, 1061-1068.	5.8	228
6	Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions. <i>Nature Communications</i> , 2021, 12, 1660.	12.8	132
7	Kidney Disease in Patients with HIV Infection and AIDS. <i>Clinical Infectious Diseases</i> , 2008, 47, 1449-1457.	5.8	95
8	Undetectable equals untransmittable (U = U): awareness and associations with health outcomes among people living with HIV in 25 countries. <i>Sexually Transmitted Infections</i> , 2021, 97, 18-26.	1.9	87
9	First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. <i>Aids</i> , 2008, 22, 1673-1675.	2.2	81
10	Transmission of Integrase Strand-Transfer Inhibitor Multidrug-Resistant HIV-1: Case Report and Response to Raltegravir-Containing Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2011, 16, 253-256.	1.0	63
11	Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. <i>Aids</i> , 2010, 24, 2019-2027.	2.2	60
12	The HIV care continuum in Latin America: challenges and opportunities. <i>Lancet Infectious Diseases, The</i> , 2015, 15, 833-839.	9.1	59
13	The HIV care cascade through time. <i>Lancet Infectious Diseases, The</i> , 2014, 14, 5-6.	9.1	58
14	Resistance Mutations in Protease and Reverse Transcriptase Genes of Human Immunodeficiency Virus Type 1 Isolates from Patients with Combination Antiretroviral Therapy Failure. <i>Journal of Infectious Diseases</i> , 1998, 178, 1497-1501.	4.0	56
15	Renal Function in Tenofovir-Exposed and Tenofovir-Unexposed Patients Receiving Highly Active Antiretroviral Therapy in the HIV Outpatient Study. <i>Journal of the International Association of Providers of AIDS Care</i> , 2007, 6, 178-187.	1.2	43
16	Low Bone Mineral Density and Risk of Incident Fracture in HIV-Infected Adults. <i>Antiviral Therapy</i> , 2016, 21, 45-54.	1.0	42
17	Effect of Zidovudine Resistance Mutations on Virologic Response to Treatment with Zidovudine+Lamivudine+Ritonavir: Genotypic Analysis of Human Immunodeficiency Virus Type 1 Isolates from AIDS Clinical Trials Group Protocol 315. <i>Journal of Infectious Diseases</i> , 2000, 181, 491-497.	4.0	41
18	Renal Function in Patients Receiving Tenofovir With Ritonavir/Lopinavir or Ritonavir/Atazanavir in the HIV Outpatient Study (HOPS) Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 43, 626-628.	2.1	38

#	ARTICLE	IF	CITATIONS
19	Lessons learned from SARS-CoV-2 measurements in wastewater. <i>Science of the Total Environment</i> , 2021, 798, 149177.	8.0	36
20	Relationship Between Polypharmacy and Quality of Life Among People in 24 Countries Living With HIV. <i>Preventing Chronic Disease</i> , 2020, 17, E22.	3.4	33
21	Physical, Emotional, and Psychosocial Challenges Associated with Daily Dosing of HIV Medications and Their Impact on Indicators of Quality of Life: Findings from the Positive Perspectives Study. <i>AIDS and Behavior</i> , 2021, 25, 961-972.	2.7	33
22	Review:Mixing New Cocktails: Drug Interactions in Antiretroviral Regimens. <i>AIDS Patient Care and STDs</i> , 2005, 19, 286-297.	2.5	32
23	Prevalence, determinants, and impact of suboptimal adherence to HIV medication in 25 countries. <i>Preventive Medicine</i> , 2020, 139, 106182.	3.4	31
24	Renal Function in Patients with Preexisting Renal Disease Receiving Tenofovir-Containing Highly Active Antiretroviral Therapy in the HIV Outpatient Study. <i>AIDS Patient Care and STDs</i> , 2009, 23, 589-592.	2.5	28
25	Shared Decision Making Between Patients and Healthcare Providers and its Association with Favorable Health Outcomes Among People Living with HIV. <i>AIDS and Behavior</i> , 2021, 25, 1384-1395.	2.7	28
26	Open-Label Study of a Twice-Daily Indinavir 800-mg/Ritonavir 100-mg Regimen in Protease Inhibitor-Naïve HIV-Infected Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 31, 478-482.	2.1	27
27	ARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine. <i>HIV Clinical Trials</i> , 2012, 13, 233-244.	2.0	27
28	Safety and Efficacy of a 36-Week Induction Regimen of Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir in HIV-Infected Patients. <i>HIV Clinical Trials</i> , 2010, 11, 69-79.	2.0	25
29	Do people with HIV infection have a higher risk of fracture compared with those without HIV infection?. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 301-305.	3.8	24
30	Acute Onset Insomnia Associated with the Initiation of Raltegravir: A Report of Two Cases and Literature Review. <i>AIDS Patient Care and STDs</i> , 2009, 23, 689-690.	2.5	21
31	A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1-Infected Patients: 48-Week Results of the SHIELD Trial. <i>HIV Clinical Trials</i> , 2010, 11, 260-269.	2.0	20
32	Inflammatory Biomarker Changes and Their Correlation with Framingham Cardiovascular Risk and Lipid Changes in Antiretroviral-Naïve HIV-Infected Patients Treated for 144 Weeks with Abacavir/Lamivudine/Atazanavir with or without Ritonavir in ARIES. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 350-358.	1.1	20
33	Bones, Fractures, Antiretroviral Therapy and HIV. <i>Current Infectious Disease Reports</i> , 2014, 16, 393.	3.0	18
34	Trends in use of genotypic resistance testing and frequency of major drug resistance among antiretroviral-naïve persons in the HIV Outpatient Study, 1999-2011. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2337-2346.	3.0	16
35	Treatment aspirations and attitudes towards innovative medications among people living with HIV in 25 countries. <i>Population Medicine</i> , 2020, 2, .	0.8	15
36	Short-Term Safety and Tolerability of Didanosine Combined with High- versus Low-Dose Tenofovir Disoproxil Fumarate in Ambulatory HIV-1-Infected Persons. <i>AIDS Patient Care and STDs</i> , 2006, 20, 238-244.	2.5	11

#	ARTICLE	IF	CITATIONS
37	Trends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study: 1999–2008. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-10.	0.7	10
38	The Complicated Evolutionary Diversification of the Mpeg-1/Perforin-2 Family in Cnidarians. <i>Frontiers in Immunology</i> , 2020, 11, 1690.	4.8	9
39	Specificity for 3',5'-linked substrates in RNA-catalyzed RNA polymerization. <i>Journal of Molecular Evolution</i> , 1989, 29, 480-485.	1.8	8
40	Regional differences in perceived treatments needs and priorities in relation to antiretroviral therapy among people living with HIV in 25 countries. <i>Preventive Medicine</i> , 2021, 142, 106372.	3.4	7
41	Treatment challenges and health conditions among people living with HIV with or without substance use disorder in the Russian Federation. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2022, 34, 1276-1281.	1.2	5
42	Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks. <i>HIV/AIDS - Research and Palliative Care</i> , 2017, Volume 9, 51-61.	0.8	4
43	Improving the fit of bivariate smoothing splines when estimating longitudinal immunological and virological markers in HIV patients with individual antiretroviral treatment strategies. <i>Statistics in Medicine</i> , 2001, 20, 2489-2504.	1.6	3
44	The Role of Nucleoside and Nucleotide Reverse Transcriptase Inhibitor Backbones in Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2004, 37, S13-S20.	2.1	3
45	Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine. <i>HIV Clinical Trials</i> , 2015, 16, 125-129.	2.0	3
46	Reply. <i>Journal of Infectious Diseases</i> , 1999, 180, 570-571.	4.0	0
47	Quantifying unmet treatment needs among people living with HIV in Australia and other countries. <i>Population Medicine</i> , 2021, 3, 1-14.	0.8	0
48	PA update: DHHS guidelines for the treatment of HIV infection. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2006, Suppl, 3-13.	0.3	0
49	Drug-drug interactions with antiretroviral therapy among people living with HIV in Asia and other regions: risk factors and impact on indicators of health-related quality of life. <i>Population Medicine</i> , 2022, 4, .	0.8	0